Onco Actu du 19 avril 2017

	1. Biologie
This tech was meant to explore space. Can it also solve the mysteries of breast cancer? [STAT] For Love, who considers the human breast about as unexplored as the surface of Mars, the collaboration with the lab is a natural fit. “This is really discovery research. We have no idea what we’re going to find,” Love said. “We’re like JPL. We just want to go and see what’s out there.”
	1.1 Biologie - Gènes
Missing Genes Point to Possible Drug Targets [NIH Director's blog] Ultimately, the hope is to enable researchers and drug developers to search a database, find a gene and a person with a corresponding knockout, and then conduct additional studies to figure out how that particular loss of the gene function affects human biology.
	2.5 Etiologie - Gènes
Discovering unknown causes of cancer through ‘fingerprints’ in DNA [Cancer Research UK] Making all this global effort work, collaborating across continents, collecting patient information and samples, is something Stratton describes as an enormous logistical challenge.
	5. Traitements
Targeting cancer spread: keeping breast tumours under LOX and key [Cancer Research UK] They then gave this inhibitor to mice that were predisposed to develop breast cancer that spreads to the lungs, and found that it not only slowed the growth of primary tumours, but also reduced the amount that spread to the lungs. Encouragingly, the scientists didn’t observe any side effects in the mice.
Precision Medicine Pioneer Targets Earlier Cancer Detection [Medscape] Dr Topol: I want to leave with a sense of what cancer treatment and prevention will look like in a decade. Dr Druker: The analogy I use is, what if we turned the clock back 100 years and looked at infectious diseases?
	5.12.2 Immunothérapies - CAR-T
Novartis gets second CAR-T candidate FDA ‘breakthrough’ tag [FierceBiotech] If Novartis does turn victor in the race to market, this will come as a major turnaround given that last year, it announced plans to cut back on its gene and cell therapy unit (which developed this drug) and saw the exodus of many of those who had helped create and nurture it.
Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps [The Street] The FDA appears to like Novartis' JULIET data well enough to drop a breakthrough label on CTL019 but how the therapy stacks up against Kite's KTE-C19 is not known quite yet.
Novartis is keeping JULIET in hiding, but the FDA takes a peek and hands over a ‘breakthrough’ title [EndPoints] We’ll have to wait for an unspecified scientific conference to find out what Novartis has been keeping secret.
	5.12.5 Immunothérapies - Pharma
Ex-Dendreon CEO, Gold, Returns to Wall Street as Alpine, Nivalis Merge [Xconomy] Mitch Gold, the controversial executive who oversaw the rise of now-defunct cancer immunotherapy pioneer Dendreon, is about to head back to Wall Street.
Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger [The Street] Once the merger is complete in the third quarter, the combined companies will take the Alpine Immune Sciences name and focus on its pipeline of protein-based immunotherapy drugs. Alpine will have $90 million in funding with shares trading on the Nasdaq.
	5.2 Pharma
Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer [Puma] The NDA for neratinib is based on results from both the Phase III ExteNET trial in extended adjuvant early stage HER2-positive breast cancer and the Phase II CONTROL trial in extended adjuvant early stage HER2-positive breast cancer.
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug [The Street] There's little about neratinib that isn't controversial, providing ample fodder for Puma bulls and bears to argue over.
	5.2.1 Pharma - Partenariats
CRT pioneer fund, Cancer Research UK and NCI collaborate to boost research against the ‘undruggable’ RAS [Cancer Research UK] This new collaboration links up with the NCI’s RAS Initiative which brings scientists together from around the globe to help develop drugs targeting the faulty protein. Launched in 2013, the initiative has established a hub of expertise that supports the international community in developments that could have huge clinical benefit.
	5.2.3 Pharma - économie
Hey Pfizer, Novartis and Eli Lilly. G1 Therapeutics says it can beat all of you in its $115M IPO [EndPoints] CEO Mark Velleca and the crew at G1 feel they have started down the path to developing CDK 4/6 drugs that can do much better than the first wave in tackling cancer.
	5.3.4 Traitements - AMM (FDA, EMA)
FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer [Roche] First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy.
	5.4 Traitements - Economie
James Raftery: NICE’s proposed new QALY modifier for appraising highly specialised technologies [BMJ Blogs] NICE now proposes to introduce “a QALY modifier,” which could raise the threshold to £300 000 for some highly specialised technologies.
	6.10.1 Politiques (USA)
Federal biomedical science policy under Donald Trump, nearly 100 days in [Respectful Insolence] The answer to everything: More deregulation and more ties with business.